Preventing relapse of major depression during interferon-α therapy for hepatitis C - A pilot study

Digestive Diseases and Sciences

Volumn 52, Issue 10, 2007, Pages 2557-2563

  Gleason, Ondria C ^a   Fucci, John C ^b   Yates, William R ^a   Philipsen, Michelle A ^a  

^a University of Oklahoma Tulsa College of Medicine   (United States)

^b ST JOHN MEDICAL CENTER   (United States)

Author keywords

Depression; Escitalopram; Hepatitis CI; Interferon; Prevention

Indexed keywords

ALPHA INTERFERON; ESCITALOPRAM; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HEALTH SURVEY; HEPATITIS C; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; SCORING SYSTEM;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; CITALOPRAM; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; RECURRENCE; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34548508884     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9729-5     Document Type: Article

References (27)

1. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Calès P, Garré JB (2003) Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 4:115-118
2. El-Serag HB, Kunik M, Richardson P, Rabeneck L (2002) Psychiatic disorders among veterans with hepatitis C infection. Gastroenterology 123:476-482
3. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292(23):2839-2848
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975-982
5. Complete Product Information and Pegasys Medication Guide (2006) Available at: http:/www.rocheusa.com/products/pegasys/ pi.pdf; retrieved July 12, 2006
6. Peg Intron (2006) Product Information Page. Rev. 02/05. Available at: http://www.spfiles.com/pipeg-intron.pdf; retrieved August 17, 2006
7. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD (2002) A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 7:942-947
8. Gleason OC, Yates WR (1999) Five cases of interferon-alfa-induced depression treated with antidepressant therapy. Psychosomatics 40:510-512
9. Levenson JL, Fallon HJ (1993) Fluoxetine treatment of depression caused by interferon-alfa. Am J Gastroenterol 88:760-761
10. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG (2000) Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 173:359-361
11. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M (2002) Paroxetine for the treatment of interferon-alfa-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 16:1091-1099
12. Goldman LS (1994) Successful treatment of interferon alfa-induced mood disorder with nortiptyline [letter]. Psychosomatics 35:412-413
13. Gleason OC, Yates WR, Isbell MD, Philipsen MA (2002) An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 36:194-198
14. Gleason OC, Yates WR, Philipsen MA (2005) Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Compan J Clin Psychiatry 7(5):225-230
15. Loftis JM, Hauser P (2003) Safety of the treatment of interferon-alpha-induced depression [letter]. Psychosomatics 44:524-526
16. Hejny C, Sternburg P, Lawson DH, Greiner K, Aaberg Jr TM (2001) Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Opthalmol 131:782-787
17. Ozcanli T, Unsalver B, Ozdemir S, Ozmen M (2005) Sertraline- and mirtazapine-induced severe neutropenia [letter]. Am J Psychiatry 162:1386
18. Choi S (2003) Nefazadone (Serzone) withdrawn because of hepatotoxicity. CMAJ 169:1187
19. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42(6):793-798
20. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM (2000) Hepatitis C, interferon alfa, and depression. Hepatology 31:1207-1211
21. Sheehan DV, Lecrubier Y, Harnett-Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview. J. Clin Psychiatry 59(Suppl 20):22-33
22. Hamilton M (1976) Hamilton Depression Scale. In: ECDEU assessment manual for psychopharmacology. Rev. ed. Guy W (ed). U.S. Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, pp 179-192
23. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
24. Berg R, Franzen M, Wedding D (1987) Screening for brain impairment: a manual for mental health practice. Springer, New York
25. Derogatis LR (2000) Symptom Checklist-90-Revised (SCL-90-R) In: Task force for the handbook of psychiatric measures. Handbook of psychiatric measures. American Psychiatric Association, Washington, DC, pp 81-84
26. Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 30:473-483
27. National Institute of Mental Health (1970) CGI: clinical global impressions. In: Manual for the ECDEU assessment battery, 2. Rev ed. Guy W, Bonato RR (eds). Chevy Chase, MD: National Institute of Mental Health, pp 12-1-12-6